Johnson & Johnson will Have 600-900 Million Coronavirus Vaccines by 2021

Johnson & Johnson (J & J) predicts that if the clinical trial is successful, it will be able to produce 900 million doses of new coronavirus (Corona 19) vaccine by April next year.

According to CNBC , J & J aims to produce 600 to 900 million doses of Corona 19 vaccine by the end of the first quarter of next year if the clinical trial scheduled for September is successful, according to a conference call after the announcement of the results.

Since then, J & J said it will produce 1 billion doses of vaccine next year.

“It’s not for profit, but for emergency use,” said Alex Goskey, chief executive officer of J & J, once again.

In the aftermath of the Corona 19, J & J proposed an estimate of earnings per share this year, down from the previous $ 8.95 to $ 9.10 to $ 7.50 to $ 7.90.

Currently, biotech companies are spurring the development of Corona19 vaccine.

U.S. health officials predicted that it would take 12-18 months to commercialize the vaccine.

Reviewer overview

Johnson & Johnson Coronavirus Vaccines by 2021 - /10

Summary

Johnson & Johnson (J & J) predicts that if the clinical trial is successful, it will be able to produce 900 million doses of new coronavirus (Corona 19) vaccine by April next year.

0 Bad!